Hemolytic anemia - Revision history

SeanDenny: /* Infection */

2020-12-14T03:09:45Z

Infection

← Revisión anterior		Revisión del 03:09 14 dic 2020
Línea 229:		Línea 229:
	**Visit CDC website to determine resistance pattern: https://www.cdc.gov/malaria/diagnosis_treatment/treatment.html		**Visit CDC website to determine resistance pattern: https://www.cdc.gov/malaria/diagnosis_treatment/treatment.html
	**CDC Malaria Hotline: (770) 488-7788 or (855) 856-4713 toll-free Monday-Friday 9 am to 5 pm EST - (770) 488-7100 after hours, weekends and holidays		**CDC Malaria Hotline: (770) 488-7788 or (855) 856-4713 toll-free Monday-Friday 9 am to 5 pm EST - (770) 488-7100 after hours, weekends and holidays
	*[[~~Babesia~~]]		*[[Babesiosis]]
	**Mild/moderate Disease		**Mild/moderate Disease
	***[[Atovaquone]] 750mg PO q12hr '''AND'''		***[[Atovaquone]] 750mg PO q12hr '''AND'''

SeanDenny: /* Infection */

2020-12-14T03:09:14Z

Infection

← Revisión anterior		Revisión del 03:09 14 dic 2020
Línea 89:		Línea 89:
	====Infection====		====Infection====
	*[[Malaria]]		*[[Malaria]]
	*[[~~Babesia~~]]		*[[Babesiosis]]

	====Other====		====Other====
	*[[Brown recluse spider venom]]		*[[Brown recluse spider venom]]

Josgood: /* Physical Exam */

2019-04-12T04:07:31Z

Physical Exam

← Revisión anterior		Revisión del 04:07 12 abr 2019
Línea 76:		Línea 76:
	**Bruising		**Bruising
	**[[Lymphadenopathy]]		**[[Lymphadenopathy]]
	**[[Brown recluse spider bites]]		**[[Brown recluse]] spider bites

	==Differential Diagnosis==		==Differential Diagnosis==

Mholtz at 01:13, 10 July 2017

2017-07-10T01:13:58Z

← Revisión anterior		Revisión del 01:13 10 jul 2017
Línea 192:		Línea 192:
	\|}		\|}

	==Management ==		==Management==
	*ABC’s and resuscitation if necessary, 2 large bore IVs		*ABC’s and resuscitation if necessary, 2 large bore IVs
	*Emergent hematology consultation if patient is very ill appearing		*Emergent hematology consultation if patient is very ill appearing

Mholtz at 06:38, 7 July 2017

2017-07-07T06:38:39Z

← Revisión anterior		Revisión del 06:38 7 jul 2017
Línea 230:		Línea 230:
	*[[Babesia]]		*[[Babesia]]
	**Mild/moderate Disease		**Mild/moderate Disease
	***[[Atovaquone]] 750mg PO q12hr ~~PLUS~~ [[~~azithromycin~~]] 500mg PO on day 1, then 250mg/day PO		***[[Atovaquone]] 750mg PO q12hr '''AND'''
			***[[Azithromycin]] 500mg PO on day 1, then 250mg/day PO
	**Severe Disease		**Severe Disease
	***~~Adult:~~ [[~~clindamycin~~]] 300-600mg IV QID or 600mg PO TID ~~PLUS~~ [[~~quinine~~]] 650mg PO TID ~~x 7~~-10 days		***[[Clindamycin]] 300-600mg IV QID '''OR''' 600mg PO TID '''AND'''
			***[[Quinine]] 650mg PO TID x7-10 days
	***Consider exchange transfusion if parasitemia >10%		***Consider exchange transfusion if parasitemia >10%
	**Supportive treatment		**Supportive treatment
Línea 256:		Línea 258:
	==See Also==		==See Also==
	*[[Anemia]]		*[[Anemia]]

	==External Links==		==External Links==


	==References==		==References==
	*Dhaliwal G, Cornett P, Tierney LM Jr. Hemolytic Anemia. Am Fam Physician. 2004 Jun 1;69(11):2599-606.		<references/>
	*Rother RP, Bell L, Hillmen P, Gladwin MT. The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma HemoglobinA Novel Mechanism of Human Disease. JAMA. 2005;293(13):1653-1662. doi:10.1001/~~jama.293.13.1653~~
	*Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Disease markers. 2015 Dec 27;2015.
	*Bain BJ. Diagnosis from the blood smear. New England Journal of Medicine. 2005 Aug 4;353(5):498-507.
	*Tefferi A. Anemia in adults: a contemporary approach to diagnosis. In Mayo Clinic Proceedings 2003 Oct 31 (Vol. 78, No. 10, pp. 1274-1280). Elsevier.
	*Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. Journal of Intensive Care. 2014;2(1):15. doi:10.1186/2052-0492-2-15.
	*McDade, Jenny et al. Brown Recluse Spider (Loxosceles reclusa) Envenomation Leading to Acute Hemolytic Anemia in Six Adolescents. The Journal of Pediatrics, Volume 156, Issue 1, 155 - 157
	*Albert E. Anderson, Paul B. Cassaday, George R. Healy. Babesiosis in Man: Sixth Documented Case American Journal of Clinical Pathology Nov 1974, 62 (5) 612 618; DOI:10.1093/ajcp/62.5.612

	[[Category:Heme/Onc]]		[[Category:Heme/Onc]]

Mholtz: Text replacement - "qid" to "QID"

2017-07-07T06:27:07Z

Text replacement - "qid" to "QID"

← Revisión anterior		Revisión del 06:27 7 jul 2017
Línea 232:		Línea 232:
	***[[Atovaquone]] 750mg PO q12hr PLUS [[azithromycin]] 500mg PO on day 1, then 250mg/day PO		***[[Atovaquone]] 750mg PO q12hr PLUS [[azithromycin]] 500mg PO on day 1, then 250mg/day PO
	**Severe Disease		**Severe Disease
	***Adult: [[clindamycin]] 300-600mg IV ~~qid~~ or 600mg PO TID PLUS [[quinine]] 650mg PO TID x 7-10 days		***Adult: [[clindamycin]] 300-600mg IV QID or 600mg PO TID PLUS [[quinine]] 650mg PO TID x 7-10 days
	***Consider exchange transfusion if parasitemia >10%		***Consider exchange transfusion if parasitemia >10%
	**Supportive treatment		**Supportive treatment

ClaireLewis: /* Microangiopathic Hemolytic Anemia */

2017-04-03T17:56:34Z

Microangiopathic Hemolytic Anemia

← Revisión anterior		Revisión del 17:56 3 abr 2017
Línea 205:		Línea 205:
	*[[TTP]]		*[[TTP]]
	**'''Avoid''' platelet transfusion, except in life-threatening bleeding or intracranial hemorrhage		**'''Avoid''' platelet transfusion, except in life-threatening bleeding or intracranial hemorrhage
	**Plasma exchange		**[[Plasma exchange]]
	**If Plasma exchange cannot be performed immediately, give FFP and plasmapharese later.		**If Plasma exchange cannot be performed immediately, give FFP and plasmapharese later.
	**Factor VIII concentrate		**Factor VIII concentrate
Línea 211:		Línea 211:
	**Platelet transfusion if count is <50,000 and/or significant bleeding		**Platelet transfusion if count is <50,000 and/or significant bleeding
	**pRBC if active bleeding or hemodynamically unstable		**pRBC if active bleeding or hemodynamically unstable
	**FFP if active bleeding		**[[FFP]] if active bleeding
	**Cryoprecipitate if fibrinogen <150 and bleeding		**[[Cryoprecipitate]] if fibrinogen <150 and bleeding
	**TXA is only indicated for active or massive bleeding		**[[TXA]] is only indicated for active or massive bleeding
	*[[Malignant hypertension]]		*[[Malignant hypertension]]
	**Reduce blood pressure as clinically indicated		**Reduce blood pressure as clinically indicated

Mholtz: Text replacement - "->" to "→"

2017-02-09T01:58:13Z

Text replacement - "->" to "→"

← Revisión anterior		Revisión del 01:58 9 feb 2017
Línea 102:		Línea 102:
	*CBC		*CBC
	**Low hemaglobin/hematocrit		**Low hemaglobin/hematocrit
	**Low platelet count -> microangiopathic hemolytic anemia		**Low platelet count → microangiopathic hemolytic anemia
	*Blood smear		*Blood smear
	*Reticulocyte count		*Reticulocyte count

ClaireLewis: /* References */

2016-10-29T16:45:07Z

References

← Revisión anterior		Revisión del 16:45 29 oct 2016
Línea 267:		Línea 267:
	*McDade, Jenny et al. Brown Recluse Spider (Loxosceles reclusa) Envenomation Leading to Acute Hemolytic Anemia in Six Adolescents. The Journal of Pediatrics, Volume 156, Issue 1, 155 - 157		*McDade, Jenny et al. Brown Recluse Spider (Loxosceles reclusa) Envenomation Leading to Acute Hemolytic Anemia in Six Adolescents. The Journal of Pediatrics, Volume 156, Issue 1, 155 - 157
	*Albert E. Anderson, Paul B. Cassaday, George R. Healy. Babesiosis in Man: Sixth Documented Case American Journal of Clinical Pathology Nov 1974, 62 (5) 612 618; DOI:10.1093/ajcp/62.5.612		*Albert E. Anderson, Paul B. Cassaday, George R. Healy. Babesiosis in Man: Sixth Documented Case American Journal of Clinical Pathology Nov 1974, 62 (5) 612 618; DOI:10.1093/ajcp/62.5.612

			[[Category:Heme/Onc]]

Neil.m.young: Text replacement - "* " to "*"

2016-10-27T16:42:49Z

Text replacement - "* " to "*"

← Revisión anterior		Revisión del 16:42 27 oct 2016
Línea 25:		Línea 25:
	**Dark urine		**Dark urine
	**Changes in stool color		**Changes in stool color
	** Neuro ([[TTP]])		**Neuro ([[TTP]])
	***[[Headache]]		***[[Headache]]
	***[[Altered mental status]]		***[[Altered mental status]]
Línea 63:		Línea 63:
	*[[Renal failure]]		*[[Renal failure]]
	*[[Connective tissue disease]]		*[[Connective tissue disease]]
	* Family history of Anemia/Bleeding		*Family history of Anemia/Bleeding

	===Physical Exam===		===Physical Exam===
Línea 70:		Línea 70:
	**Heart murmur – prosthetic heart valve		**Heart murmur – prosthetic heart valve
	*Abdominal Exam		*Abdominal Exam
	** Hepatomegaly, splenomegaly		**Hepatomegaly, splenomegaly
	**[[Ascites]]		**[[Ascites]]
	*Skin		*Skin
Línea 100:		Línea 100:
	==Evaluation==		==Evaluation==
	===Workup===		===Workup===
	* CBC		*CBC
	**Low hemaglobin/hematocrit		**Low hemaglobin/hematocrit
	**Low platelet count -> microangiopathic hemolytic anemia		**Low platelet count -> microangiopathic hemolytic anemia
	* Blood smear		*Blood smear
	* Reticulocyte count		*Reticulocyte count
	* CMP		*CMP
	** Most important: indirect bilirubin and creatinine		**Most important: indirect bilirubin and creatinine
	* [[UA]] (for hemoglobin, hemosiderin), uHCG		*[[UA]] (for hemoglobin, hemosiderin), uHCG
	* PT/INR		*PT/INR
	* Hemolysis labs		*Hemolysis labs
	**LDH		**LDH
	**Haptoglobin		**Haptoglobin
	**Fibrinogen		**Fibrinogen
	* Direct Anti-Globulin Test or Coombs test		*Direct Anti-Globulin Test or Coombs test
	* If concern for Malaria:		*If concern for Malaria:
	**Thick and thin prep		**Thick and thin prep
	**Parasitemia		**Parasitemia
Línea 206:		Línea 206:
	**'''Avoid''' platelet transfusion, except in life-threatening bleeding or intracranial hemorrhage		**'''Avoid''' platelet transfusion, except in life-threatening bleeding or intracranial hemorrhage
	**Plasma exchange		**Plasma exchange
	** If Plasma exchange cannot be performed immediately, give FFP and plasmapharese later.		**If Plasma exchange cannot be performed immediately, give FFP and plasmapharese later.
	**Factor VIII concentrate		**Factor VIII concentrate
	*[[DIC]]		*[[DIC]]
Línea 226:		Línea 226:
	====Infection====		====Infection====
	*[[Malaria]]		*[[Malaria]]
	** Visit CDC website to determine resistance pattern: https://www.cdc.gov/malaria/diagnosis_treatment/treatment.html		**Visit CDC website to determine resistance pattern: https://www.cdc.gov/malaria/diagnosis_treatment/treatment.html
	** CDC Malaria Hotline: (770) 488-7788 or (855) 856-4713 toll-free Monday-Friday 9 am to 5 pm EST - (770) 488-7100 after hours, weekends and holidays		**CDC Malaria Hotline: (770) 488-7788 or (855) 856-4713 toll-free Monday-Friday 9 am to 5 pm EST - (770) 488-7100 after hours, weekends and holidays
	*[[Babesia]]		*[[Babesia]]
	**Mild/moderate Disease		**Mild/moderate Disease
	***[[Atovaquone]] 750mg PO q12hr PLUS [[azithromycin]] 500mg PO on day 1, then 250mg/day PO		***[[Atovaquone]] 750mg PO q12hr PLUS [[azithromycin]] 500mg PO on day 1, then 250mg/day PO
	**Severe Disease		**Severe Disease
	*** Adult: [[clindamycin]] 300-600mg IV qid or 600mg PO TID PLUS [[quinine]] 650mg PO TID x 7-10 days		***Adult: [[clindamycin]] 300-600mg IV qid or 600mg PO TID PLUS [[quinine]] 650mg PO TID x 7-10 days
	***Consider exchange transfusion if parasitemia >10%		***Consider exchange transfusion if parasitemia >10%
	**Supportive treatment		**Supportive treatment
Línea 260:		Línea 260:
	==References==		==References==
	*Dhaliwal G, Cornett P, Tierney LM Jr. Hemolytic Anemia. Am Fam Physician. 2004 Jun 1;69(11):2599-606.		*Dhaliwal G, Cornett P, Tierney LM Jr. Hemolytic Anemia. Am Fam Physician. 2004 Jun 1;69(11):2599-606.
	* Rother RP, Bell L, Hillmen P, Gladwin MT. The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma HemoglobinA Novel Mechanism of Human Disease. JAMA. 2005;293(13):1653-1662. doi:10.1001/jama.293.13.1653		*Rother RP, Bell L, Hillmen P, Gladwin MT. The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma HemoglobinA Novel Mechanism of Human Disease. JAMA. 2005;293(13):1653-1662. doi:10.1001/jama.293.13.1653
	*Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Disease markers. 2015 Dec 27;2015.		*Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Disease markers. 2015 Dec 27;2015.
	*Bain BJ. Diagnosis from the blood smear. New England Journal of Medicine. 2005 Aug 4;353(5):498-507.		*Bain BJ. Diagnosis from the blood smear. New England Journal of Medicine. 2005 Aug 4;353(5):498-507.
	* Tefferi A. Anemia in adults: a contemporary approach to diagnosis. In Mayo Clinic Proceedings 2003 Oct 31 (Vol. 78, No. 10, pp. 1274-1280). Elsevier.		*Tefferi A. Anemia in adults: a contemporary approach to diagnosis. In Mayo Clinic Proceedings 2003 Oct 31 (Vol. 78, No. 10, pp. 1274-1280). Elsevier.
	*Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. Journal of Intensive Care. 2014;2(1):15. doi:10.1186/2052-0492-2-15.		*Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. Journal of Intensive Care. 2014;2(1):15. doi:10.1186/2052-0492-2-15.
	* McDade, Jenny et al. Brown Recluse Spider (Loxosceles reclusa) Envenomation Leading to Acute Hemolytic Anemia in Six Adolescents. The Journal of Pediatrics, Volume 156, Issue 1, 155 - 157		*McDade, Jenny et al. Brown Recluse Spider (Loxosceles reclusa) Envenomation Leading to Acute Hemolytic Anemia in Six Adolescents. The Journal of Pediatrics, Volume 156, Issue 1, 155 - 157
	* Albert E. Anderson, Paul B. Cassaday, George R. Healy. Babesiosis in Man: Sixth Documented Case American Journal of Clinical Pathology Nov 1974, 62 (5) 612 618; DOI:10.1093/ajcp/62.5.612		*Albert E. Anderson, Paul B. Cassaday, George R. Healy. Babesiosis in Man: Sixth Documented Case American Journal of Clinical Pathology Nov 1974, 62 (5) 612 618; DOI:10.1093/ajcp/62.5.612